CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code For Conexxence And Bomyntra

RefinitivMeno di 1 minuto di lettura

Fresenius Kabi Oncology Ltd (FRES.M3):

CMS GRANTS FRESENIUS KABI PERMANENT, PRODUCT-SPECIFIC Q-CODE FOR CONEXXENCE® AND BOMYNTRA® (DENOSUMAB-BNHT)

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Accedi o crea un account gratuito per leggere queste notizie